Posted by Michael Wonder on 03 Jul 2023
Novartis’ Scemblix gets benefit to treat chronic myeloid leukaemia third or more times
30 June 2023 - Novartis' Scemblix (asciminib) will receive reimbursement for the third-line or more treatment of chronic myeloid leukaemia patients in Korea starting next month.
HIRA said Thursday that it has revised and published details on the criteria and methodology for medical benefits for drugs prescribed and administered to cancer patients.
